| __timestamp | Eli Lilly and Company | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 49315000 |
| Thursday, January 1, 2015 | 6533000000 | 75043000 |
| Friday, January 1, 2016 | 6452000000 | 83749000 |
| Sunday, January 1, 2017 | 6588100000 | 122682000 |
| Monday, January 1, 2018 | 5975100000 | 207761000 |
| Tuesday, January 1, 2019 | 6213800000 | 284812000 |
| Wednesday, January 1, 2020 | 6121200000 | 317875000 |
| Friday, January 1, 2021 | 6431600000 | 282660000 |
| Saturday, January 1, 2022 | 6440400000 | 451421000 |
| Sunday, January 1, 2023 | 6941200000 | 481871000 |
| Monday, January 1, 2024 | 8593800000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Eli Lilly and Company, a stalwart in the sector, has consistently demonstrated robust SG&A management. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady trend, peaking at approximately $6.9 billion in 2023, reflecting a modest increase of around 5% from 2014.
In contrast, Sarepta Therapeutics, Inc., a burgeoning player, has seen its SG&A expenses grow significantly, from about $49 million in 2014 to nearly $482 million in 2023. This tenfold increase underscores Sarepta's aggressive expansion strategy.
This analysis highlights the contrasting strategies of a well-established giant and an ambitious newcomer, offering insights into their operational efficiencies and market approaches.
Eli Lilly and Company vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Eli Lilly and Company or Insmed Incorporated: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Viatris Inc.
Breaking Down SG&A Expenses: Eli Lilly and Company vs CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Protagonist Therapeutics, Inc.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Sarepta Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Jazz Pharmaceuticals plc
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Verona Pharma plc
Sarepta Therapeutics, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Novavax, Inc.